Abstract 4579
Background
Late lines of therapy (LL) offered to cancer patients (pts) are often characterized by scarce or doubtful clinical benefit and literature evidences about their use and their real impact on survival and quality of life are very few. ESMO-MCBS (ESMO Magnitude of Benefit Scale) is a tool that gives an evaluation of the magnitude of clinically meaningful benefit that can be expected from anti-tumour therapies. The aim of our study was to evaluate ESMO-MCBS of the treatments that were offered as a LL to pts in our centre and to perform an evaluation of the clinical assistance they received.
Methods
We calculated ESMO-MCBS of the therapies that were offered as LL to pts that were treated at our centre and whose death happened in the period from January 1st, 2017 to December 31st, 2018. We also evaluated these pts’rate of unplanned access to emergency room or hospitalizations and their access to supportive care and palliative care service in the last 90 days of their lives.
Results
238 pts were included in the analysis. 12 (5.04%) pts received a LL with a high ESMO-MCBS (4 or 5), 16 (6.72%) a LL with an intermediate ESMO-MCBS, 77 (32.35%) a LL with a low ESMO-MCBS (1 or 2), and 133 (55.88%) a LL whose ESMO-MCBS could not be calculated because of lack of data from strong literature evidences (e.g. phase-3 trials) that are required for the scale. 79 pts (33.19%) had at least an unplanned access to emergency room or hospitalization during the last 90 days before death. 117 pts (49.16%) accessed at least once to our supportive and palliative care service in the same timeframe.
Conclusions
Our study confirmed that patients are often offered a LL whose clinical benefit is little, absent or unevaluable. Merely half of these pts are addressed to supportive/palliative care service whose clinical impact is high in this setting. On the one hand, we then strongly suggest integrating ESMO-MCBS as a clinical tool for the evaluation of possible LL offered to advanced-stage pts in order to prevent them from receiving therapies of poor clinical impact. On the other hand it becomes mandatory to offer these pts a timely access to valuable, more precocious supportive and palliative care, which can positively impact on their quality of life in the last months of their lives.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5314 - Spirituality and religious coping for Cancer patients and providers: An ‘Almighty’ belief for palliative care
Presenter: Vibhay Pareek
Session: Poster Display session 1
Resources:
Abstract
5519 - Is there a difference of Palliative care problems and needs between cancer and non-cancer hospitalized elderly patients?
Presenter: Ioanna Chatzi
Session: Poster Display session 1
Resources:
Abstract
2505 - There is a lack of clinical research for patients with cancer in palliative care
Presenter: Marie Vinches
Session: Poster Display session 1
Resources:
Abstract
5273 - Specialist Palliative Care (SPC) in Haematological Malignancy: Establishing practices in a UK Tertiary Cancer Centre (TCC)
Presenter: Emma Kedgley
Session: Poster Display session 1
Resources:
Abstract
5864 - Evaluation of the relationship between the attachment styles and psychological resilience of cancer patients receiving chemotherapy
Presenter: Fatma Bugdayci Basal
Session: Poster Display session 1
Resources:
Abstract
770 - Gefitinib along with Methotrexate as palliative therapy in PS 3 and above in metastatic squamous cell carcinoma head and neck cancer patients
Presenter: Vidya Dusi
Session: Poster Display session 1
Resources:
Abstract
4232 - High intensity end-of-life care in pediatrics, adolescent and young adult patients with cancer using an administrative database.
Presenter: Seiko Bun
Session: Poster Display session 1
Resources:
Abstract
4845 - Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital
Presenter: Deniz Can Guven
Session: Poster Display session 1
Resources:
Abstract
3270 - Internet-based stepped care for individuals with cancer and concurrent anxiety or depression symptoms – results from a randomized controlled trial
Presenter: Birgitta Johansson
Session: Poster Display session 1
Resources:
Abstract
5503 - Impact of Cognitive-Behavioral-Therapy (CBT) on levels of anxiety, depression and distress in cancer patients (pts)
Presenter: Daniela Tregnago
Session: Poster Display session 1
Resources:
Abstract